Identity

A highly contagious, lymphoproliferative neoplastic viral disease affecting long-lived layers. Caused by a cell-associated, double-stranded DNA virus, it targets the oncogenic and nervous systems, leading to T-cell lymphomas, paralysis, and severe immunosuppression.

Overview

Marek's Disease is a critical viral infectious pathogen that primarily affects long-lived poultry species (layers). MDV-1 replicates in B-lymphocytes before establishing latency in CD4+ T-lymphocytes, culminating in neoplastic transformation and the formation of visceral lymphomas. It targets the nervous system and skin, causing paralysis and tumors. There is no treatment. Prevention relies entirely on administering vaccines (Marek's HVT, SB-1, CVI988/Rispens, HVT-ND Recombinant) in-ovo at 18 days or at the hatchery on Day 0. These cell-associated vaccines require rigorous cryogenic storage (-196°C). MDV-induced immunosuppression leads to severe secondary vaccine failures.

Structured Facts

Classification

Viral > Infectious Pathogen

Epidemiology

• Severity: High
• Affected Species: Poultry (Long-lived layers specified)
• Affected Age: Targets long-lived birds; typical clinical age 12 to 24 weeks
• Transmission: Horizontal transmission via inhalation of infectious dander/feather debris
• Mortality: Approaching 80% to 100% of clinically affected birds
• Morbidity: 10% to 50% in unvaccinated flocks
• Economic Importance: High (carcass condemnation, high mortality)

Clinical Signs

• Early/Intermediate: Long incubation (3-4 weeks to months)
• Advanced: Asymmetrical paralysis ("range paralysis"), distorted iris/blindness ("gray eye"), cutaneous nodular elevations; targets Oncogenic/Nervous system
• Postmortem Findings: Unilateral or bilateral enlargement of peripheral nerves (sciatic, brachial, vagus) losing striation. Visceral lymphomas (diffuse/nodular gray-white masses in liver, spleen, kidneys, heart, proventriculus).

Diagnosis

• Field Diagnosis: Progressive asymmetrical paralysis, "gray eye", cutaneous nodules
• Laboratory Tests: Histopathology (pleomorphic lymphoid cell infiltration in nerves), PCR targeting meq oncogene, immunohistochemical detection
• Differential Diagnosis: Avian Leukosis, Reticuloendotheliosis, Vitamin B deficiencies

Treatment

• Medicines: None exist

Prevention

• Vaccination: Marek's HVT, SB-1, CVI988/Rispens (Subcutaneous Day 0), HVT-ND Recombinant (Subcutaneous/In-ovo at 18 days)
• Biosecurity: Mitigated by standard Biosecurity Protocols
• Farm Management: Requires cryogenic storage in liquid nitrogen silos (-196°C) for cell-associated vaccines

Quantitative Data

• Morbidity Rate: 10% to 50% (unvaccinated)
• Mortality Rate: 80% to 100% (in clinically affected)
• Storage Temperature: -196°C (Cryogenic liquid nitrogen silos)
• Vaccination Day: In-ovo at 18 days or Day 0

Relationships

• Vaccines: Marek's HVT, HVT-ND Recombinant, SB-1, CVI988/Rispens
• Medicines: None
• Breed Susceptibility: Long-lived layers
• Equipment: Liquid Nitrogen Silos (LN2 Silos)
• Predisposing Relationships: Severe immunosuppression causing secondary vaccination failure (Chicken Infectious Anemia, etc.)